10 completed, 7 terminated, 1 active not recruiting. 10 Phase 3, 3 Phase 1, 3 Phase 2, 1 Not applicable, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Completed 6, Terminated 4 |
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 3 | Active not recruiting 1, Completed 1, Terminated 1 |
| Not applicable | 1 | Terminated 1 |
| Phase 4 | 1 | Terminated 1 |
Follow flibanserin: new trials by email Literature Review of flibanserin trials Research Report on flibanserin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer Flibanserin 100 MG, Placebo, Androgen deprivation therapy - Prostate Adenocarcinoma | Phase 2 | Completed | Andrew McDonald | 44 | 2021-07-02 | 2026-07-20 |
| Hypoactive Sexual Desire Disorder in Males Flibanserin, Placebo - Low Libido | Phase 2 | Terminated | Mohit Khera | 8 | 2020-05-08 | 2026-01-26 |
| Bioequivalence Study of Flibanserin From AphroFemine 100 mg F.C.T (Bio Med for Pharmaceuticals Industries (BIOMED), Egypt) Versus Addyi 100 mg Tablets (Sprout Pharmaceuticals, Inc., USA) Flibanserin 100Mg Tab, Flibanserin 100 MG [Addyi] - Healthy | Phase 1 | Completed | Genuine Research Center, Egypt | 26 | 2018-12-12 | 2020-07-31 |
| A Study of Flibanserin in Breast Cancer Survivors on Tamoxifen or Aromatase Inhibitors Flibanserin Pill - Breast Cancer, Hyposexual Desire Disorder | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 43 | 2018-09-14 | 2026-11-04 |
| Flibanserin (Addyi®) vs. Flibanserin and Sex Therapy sex therapy, flibanserin - Hypoactive Sexual Desire Disorder | Phase 4 | Terminated | San Diego Sexual Medicine | 23 | 2017-01-25 | 2022-06-13 |
| Effects of Flibanserin on the Pre- and Post-menopausal Female Brain Flibanserin, Placebo - Hypoactive Sexual Desire Disorder | Not applicable | Terminated | University of Chicago | 57 | 2016-10-01 | 2024-05-16 |
| Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD) flibanserin 100 mg dose every evening - Sexual Dysfunctions, Psychological | Phase 1 | Completed | Sprout Pharmaceuticals, Inc | 24 | 2010-07-01 | 2014-05-21 |
| to Evaluate Effect of Multi Doses Flibans 100 mg Film-c Tablets on Single Dose PK of Digoxin 0.5 mg, Healthy Volunteers Flibanserin plus Digoxin, Digoxin - Healthy | Phase 1 | Completed | Boehringer Ingelheim | 24 | 2010-06-01 | 2011-04-08 |
| A 28-week Safety Study of Flibanserin in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder flibanserin - Sexual Dysfunctions, Psychological | Phase 3 | Terminated | Sprout Pharmaceuticals, Inc | 596 | 2010-04-01 | 2014-05-12 |
| 12 Week Safety Trial of Flibanserin in Depressed Women Taking an SSRI or SNRI With Decreased Sexual Desire and Distress flibanserin 50 mg to 100 mg qhs, flibanserin 100 mg qhs, placebo 2 tablets qhs - Sexual Dysfunctions, Psychological, Depression | Phase 3 | Terminated | Sprout Pharmaceuticals, Inc | 111 | 2010-01-01 | 2016-08-24 |
| Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North America Flibanserin, Placebo - Sexual Dysfunctions, Psychological | Phase 3 | Terminated | Sprout Pharmaceuticals, Inc | 748 | 2010-01-01 | 2014-06-17 |
| Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women flibanserin, placebo - Sexual Dysfunctions, Psychological | Phase 3 | Completed | Sprout Pharmaceuticals, Inc | 949 | 2009-10-01 | 2014-06-12 |
| Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder Flibanserin, Placebo - Sexual Dysfunctions, Psychological | Phase 3 | Completed | Sprout Pharmaceuticals, Inc | 1090 | 2009-10-01 | 2014-05-19 |
| A One-year Safety Study of Flibanserin to Treat Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD). Flibanserin - Sexual Dysfunctions, Psychological | Phase 3 | Terminated | Sprout Pharmaceuticals, Inc | 1723 | 2007-02-01 | 2014-06-13 |
| Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder flibanserin, flibanserin 50mg, flibanserin 100mg - Sexual Dysfunctions, Psychological | Phase 3 | Completed | Sprout Pharmaceuticals, Inc | 1584 | 2006-07-01 | 2016-06-27 |
| 24-week Placebo-controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder flibanserin - Sexual Dysfunctions, Psychological | Phase 3 | Completed | Sprout Pharmaceuticals, Inc | 880 | 2006-07-01 | 2016-06-27 |
| 6-mo. Min Eff Dose of Flibanserin: 25 v 50 mg Bid v 50 mg hs v Pbo in Younger Women in NA flibanserin, placebo - Sexual Dysfunctions, Psychological | Phase 3 | Completed | Sprout Pharmaceuticals, Inc | 1385 | 2006-07-01 | 2016-06-27 |
| Flibanserin Randomized Withdrawal Trial in Pre-menopausal Women Flibanserin - Sexual Dysfunctions, Psychological | Phase 3 | Completed | Sprout Pharmaceuticals, Inc | 749 | 2006-01-01 | 2012-03-16 |
Sexual Dysfunctions, Psychological (13) · Breast Neoplasms (1) · Depression (1) · Erectile Dysfunction (1)
Sprout Pharmaceuticals, Inc (11) · Andrew McDonald (1) · Boehringer Ingelheim (1) · Genuine Research Center, Egypt (1) · Memorial Sloan Kettering Cancer Center (1) · Mohit Khera (1) · San Diego Sexual Medicine (1) · University of Chicago (1)
United States (16) · Canada (6) · Egypt (1) · Germany (1)
Ahmed Elshafeey, Ph.D. Pharma (1) · Andrew McDonald, MD (1) · Irwin Goldstein, MD (1) · Jon E Grant, MD, JD, MPH (1) · Mohit Khera, MD, MBA, MPH (1) · Shari Goldfarb, MD (1) · Stephanie Cacioppo, PhD (1)
PMID 22239862, PMID 22248038, PMID 23057791, PMID 24281236, PMID 28583342, PMID 29502984
R21CA259808 (1)